Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial Publisher Pubmed

Maghbooli Z¹ ; Sahraian MA¹ ; Jamalimoghadamsiahkali S² ; Asadi A³ ; Zarei A⁴ ; Zendehdel A⁵ ; Varzandi T¹ ; Mohammadnabi S¹ ; Alijani N⁶ ; Karimi M⁴ ; Shirvani A⁷ ; Holick MF⁷

Show Affiliations

1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Infectious Disease, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Infectious Disease, Shohada Pakdasht Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Scinces, Tehran, Iran
6. Department of Infectious Disease, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
7. Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, MA, United States

Source: Endocrine Practice Published:2021

Abstract

Objective: The goal of this randomized, double-blinded, placebo-controlled clinical trial was to investigate the therapeutic efficacy of oral 25-hydroxyvitamin D3 (25(OH)D3) in improving vitamin D status in vitamin D–deficient/vitamin D–insufficient patients infected with the SARS-CoV-2 (COVID-19) virus. Methods: This is a multicenter, randomized, double-blinded, placebo-controlled clinical trial. Participants were recruited from 3 hospitals that are affiliated to [Institution Blinded for Review] and [Institution Blinded for Review]. Results: A total 106 hospitalized patients who had a circulating 25(OH)D3 concentration of <30 ng/mL were enrolled in this study. Within 30 and 60 days, 76.4% (26 of 34) and 100% (24 of 24) of the patients who received 25(OH)D3 had a sufficient circulating 25(OH)D3 concentration, whereas ≤12.5% of the patients in the placebo group had a sufficient circulating 25(OH)D3 concentration during the 2-month follow-up. We observed an overall lower trend for hospitalization, intensive care unit duration, need for ventilator assistance, and mortality in the 25(OH)D3 group compared with that in the placebo group, but differences were not statistically significant. Treatment with oral 25(OH)D3 was associated with a significant increase in the lymphocyte percentage and decrease in the neutrophil-to-lymphocyte ratio in the patients. The lower neutrophil-to-lymphocyte ratio was significantly associated with reduced intensive care unit admission days and mortality. Conclusion: Our analysis indicated that oral 25(OH)D3 was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 that resulted in improved immune function by increasing blood lymphocyte percentage. Randomized controlled trials with a larger sample size and higher dose of 25(OH)D3 may be needed to confirm the potential effect of 25(OH)D3 on reducing clinical outcomes in patients with COVID-19. © 2021 AACE

Related Docs

View other Related Docs

1. Investigating the Effects of 25-Hydroxyvitamin D3 on Clinical Outcomes in Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial- a Pilot Study, Multiple Sclerosis and Related Disorders (2024)

2. Dietary Patterns and Micronutrients in Respiratory Infections Including Covid-19: A Narrative Review, BMC Public Health (2024)

3. Vitamin D Sufficiency, a Serum 25-Hydroxyvitamin D at Least 30 Ng/Ml Reduced Risk for Adverse Clinical Outcomes in Patients With Covid-19 Infection, PLoS ONE (2020)

4. The Effect of Supplementation With Vitamins A, B, C, D, and E on Disease Severity and Inflammatory Responses in Patients With Covid-19: A Randomized Clinical Trial, Trials (2021)

5. Pathological Effects of Sars-Cov-2 on Hematological and Immunological Cells: Alterations in Count, Morphology, and Function, Pathology Research and Practice (2022)

6. Role of Vitamin D in Pathogenesis and Severity of Covid-19 Infection, Archives of Physiology and Biochemistry (2023)

7. Association of Vitamin D Receptor Gene Polymorphisms and Clinical/Severe Outcomes of Covid-19 Patients, Infection# Genetics and Evolution (2021)

8. Association Between Cardiometabolic Risk Factors and Covid-19 Susceptibility, Severity and Mortality: A Review, Journal of Diabetes and Metabolic Disorders (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (17)

Alireza Abdollahi (5)

Style	Citing Format
MLA	Maghbooli Z, et al.. "Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial." Endocrine Practice, vol. 27, no. 12, 2021, pp. 1242-1251.
APA	Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF (2021). Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocrine Practice, 27(12), 1242-1251.
Chicago	Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, et al.. "Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial." Endocrine Practice 27, no. 12 (2021): 1242-1251.
Harvard	Maghbooli Z et al. (2021) 'Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial', Endocrine Practice, 27(12), pp. 1242-1251.
Vancouver	Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, et al.. Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocrine Practice. 2021;27(12):1242-1251.
BibTex	@article{ author = {Maghbooli Z and Sahraian MA and Jamalimoghadamsiahkali S and Asadi A and Zarei A and Zendehdel A and Varzandi T and Mohammadnabi S and Alijani N and Karimi M and Shirvani A and Holick MF}, title = {Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial}, journal = {Endocrine Practice}, volume = {27}, number = {12}, pages = {1242-1251}, year = {2021} }
RIS	TY - JOUR AU - Maghbooli Z AU - Sahraian MA AU - Jamalimoghadamsiahkali S AU - Asadi A AU - Zarei A AU - Zendehdel A AU - Varzandi T AU - Mohammadnabi S AU - Alijani N AU - Karimi M AU - Shirvani A AU - Holick MF TI - Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial JO - Endocrine Practice VL - 27 IS - 12 SP - 1242 EP - 1251 PY - 2021 ER -

Style

Citing Format

MLA

Maghbooli Z, et al.. "Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial." Endocrine Practice, vol. 27, no. 12, 2021, pp. 1242-1251.

APA

Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF (2021). Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocrine Practice, 27(12), 1242-1251.

Chicago

Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, et al.. "Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial." Endocrine Practice 27, no. 12 (2021): 1242-1251.

Harvard

Maghbooli Z et al. (2021) 'Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial', Endocrine Practice, 27(12), pp. 1242-1251.

Vancouver

Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, et al.. Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocrine Practice. 2021;27(12):1242-1251.

BibTex

@article{ author = {Maghbooli Z and Sahraian MA and Jamalimoghadamsiahkali S and Asadi A and Zarei A and Zendehdel A and Varzandi T and Mohammadnabi S and Alijani N and Karimi M and Shirvani A and Holick MF}, title = {Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial}, journal = {Endocrine Practice}, volume = {27}, number = {12}, pages = {1242-1251}, year = {2021} }

RIS

TY - JOUR
AU - Maghbooli Z
AU - Sahraian MA
AU - Jamalimoghadamsiahkali S
AU - Asadi A
AU - Zarei A
AU - Zendehdel A
AU - Varzandi T
AU - Mohammadnabi S
AU - Alijani N
AU - Karimi M
AU - Shirvani A
AU - Holick MF
TI - Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
JO - Endocrine Practice
VL - 27
IS - 12
SP - 1242
EP - 1251
PY - 2021
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract